肾小球疾病的管理与治疗(第二部分):KDIGO争议会议结论
本报告总结了关于原发性足细胞病、狼疮肾炎、ANCA相关肾炎、补体介导肾病和肾脏意义单克隆丙种球蛋白病的讨论。
要点
- 会议聚焦2012年KDIGO肾小球肾炎指南后的新证据与争议。
- 讨论覆盖原发性足细胞病、狼疮肾炎、ANCA相关肾炎等五类疾病。
- 报告旨在识别共识与争议领域,非形成新推荐。
核心结论
- 会议总结了五类肾小球疾病在发病机制、生物标志物和治疗方面的共识与争议。
主要发现
- 报告总结了原发性足细胞病、狼疮肾炎、ANCA相关肾炎、补体介导肾病和肾脏意义单克隆丙种球蛋白病的讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In November 2017, the Kidney Disease: Improving Global Outcomes (KDIGO) initiative brought a diverse panel of experts in glomerular diseases together to discuss the 2012 KDIGO glomerulonephritis guideline in the context of new developments and insights that had occurred over the years since its publication. During this KDIGO Controversies Conference on Glomerular Diseases, the group examined data on disease pathogenesis, biomarkers, and treatments to identify areas of consensus and areas of controversy. This report summarizes the discussions on primary podocytopathies, lupus nephritis, anti-neutrophil cytoplasmic antibody-associated nephritis, complement-mediated kidney diseases, and monoclonal gammopathies of renal significance.
引用
- Rovin BH, Caster DJ, Cattran DC, et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2019. PMID: 30665569. doi:10.1016/j.kint.2018.11.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。